Eye drop to reduce redness in adults with irritated eyes
Official title: A Multicenter, Randomized, Vehicle-Controlled Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness in Adult Subjects
Run by Alcon Research · NCT07578363 · Data updated 2026-11-12
This trial tests if an eye drop containing apraclonidine 0.125% can quickly reduce redness in adults with minor eye irritation compared with a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 178 (estimated) |
| Sponsor | Alcon Research Industry-sponsored |
| Locations | 5 sites (Northbrook, Illinois and 4 other locations) |
| Status | Recruiting |
| Started | September 27, 2026 |
| Main results expected | January 2027 |
| Study ends | March 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT07578363 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with baseline ocular redness (at least 0.5 in one eye and greater than 1 on the 5-point scale in both eyes) who have used redness-relief drops or would benefit from them, and who can comply with study visits and instructions.
✕Probably not a fit
Individuals without persistent redness or those whose redness does not respond to topical drops may see little to no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 3 interventional study evaluating the efficacy and safety of Apraclonidine Ophthalmic Solution, 0.125% versus vehicle in adults with ocular redness from minor irritation. Participants will have six in-office visits over about 10 weeks and will self-administer one drop in each eye twice daily for roughly eight weeks. The study includes a single in-eye dose on Day 1, followed by a 1-week washout after the final in-office dose before a final visit on Day 63. Redness will be measured at predefined timepoints to determine the treatment effect and safety.
Why it matters
Potential benefit: If successful, participants could experience faster and greater relief from ocular redness due to minor irritations.
How similar studies have gone: Prior studies with adrenergic eye drops for redness have shown variable but promising results in reducing redness compared with placebo.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form. * Willing and able to follow all instructions and attend all study visits. * History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion. * Baseline ocular redness score of 0.5 unit or higher in at least one eye at Visit 1 and greater than 1 unit on a 5-point scale in both eyes prior to randomization at Visit 2. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol. * Ocular surgical interventions within 6 months prior to Visit 1 or during the study. * Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters. * Use of prohibited medications, devices, or treatments as specified in the protocol. * Out of range vital signs (blood pressure and/or pulse rate) as defined in the study protocol. * Abnormal intraocular pressure. * Other protocol-defined exclusion criteria may apply.
Where it's running
-
Oculus Research, Inc.
Garner, North Carolina, United States Recruiting -
Total Eye Care PA
Memphis, Tennessee, United States Recruiting -
Piedmont Eye Center
Lynchburg, Virginia, United States Recruiting -
Wyse Eyecare
Northbrook, Illinois, United States Not yet recruiting -
CORE, Inc.
Shelby, North Carolina, United States Not yet recruiting
Study contacts
- Study coordinator: Alcon Call Center
- Email: alcon.medinfo@alcon.com
- Phone: 1-888-451-3937
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Eye drop for redness in adults: relief with a new ophthalmic solution
This study tests whether a new eye drop can reduce redness in adults with minor eye irritation or irritation-related redness.
-
Agreement of Two OCT Biometers: A Pilot Study
This pilot study tests whether two OCT biometers, UNITY Dx and Anterion, produce comparable eye measurements for adults across several eye-conditions to help guide IOL power decisions.
-
Unity DX Cornea Study
This study tests a new biometer to see how well it measures corneal and epithelial thickness compared with existing devices in adults with normal, abnormal, or post-surgery eyes.
-
Comparison of a new trifocal IOL with PanOptix Pro IOL in cataract surgery
This study tests whether the investigational trifocal IOL LPYWT0 works as well as the PanOptix Pro trifocal IOL in people with cataracts undergoing cataract surgery in both eyes.
-
Clareon TruPlus IOLs in Bilateral Cataract Surgery
This study tests Clareon TruPlus Monofocal IOLs to see how safe they are and how well they perform for people with both eyes affected by cataracts.
-
Comparing surgery times for UNITY® VCS and CONSTELLATION® Vision System
This study will see if the UNITY® VCS or the CONSTELLATION® Vision System leads to shorter combined cataract and vitrectomy (phacovitrectomy) surgery times for adults planned for 25‑gauge procedures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.